National projects
Range:
Development of NOD2 agonists and dual NOD2/TLR7 agonistic conjugates as novel vaccine adjuvants
Currently, our world is facing an acute shortage of novel vaccine adjuvants. Adjuvants enhance the immunogenicity of vaccines, therefore they constitute essential components of vaccines. They are needed not only to increase the magnitude of the response but also to guide the type of response to produce the most effective type of immunity against distinct pathogens/t...
01. July 2018 - 30. June 2022 | 3.01 Medical sciences/ Microbiology and immunology
Discovery of new inhibitors of bacterial peptidoglycan biosynthesis enzymes MurA and MurB
Nowadays, we are in a transition era where it is evident that therapy of bacterial infections is not a trivial task, understood by modern medicine and supplied with abundant medicines. Emergence of bacterial resistance, globalisation and access to modern medicinal practice together with a decreasing output of antibacterial discovery pipeline, projects a major concer...
01. May 2017 - 30. April 2019 | 1-09 Natural sciences and Mathematics - Pharmacy
Development of multifunctional compounds for treatment of Alzheimer's disease
The ageing of the population has resulted in an increase in the number of people with age-related diseases such as dementia. With more than 35 million people affected worldwide, Alzheimer’s disease (AD) is the most prominent form of senile dementia. The number of patients afflicted with this progressive neurodegenerative disorder will continue to grow and is e...
30. April 2017 - 30. April 2020 | 1-09 Natural sciences and Mathematics - Pharmacy
Cathepsin X inhibitors impair the resistence of tumor cells to antiprotease therapy
The progression of malignant diseases is associated with excessive activity of the proteolytic enzymes involved in tumor growth, angiogenesis, migration, invasion and metastasis. Among them is a group of cysteine cathepsins that are present in normal cells in endosomes and lysosomes and are responsible for intracellular protein catabolism. In tumor cells these enzym...
01. May 2017 - 30. April 2020 | 4.06.01 Biotechnical sciences-Biotechnology-Recombinant DNA technology